- Home
- RDHL vs XBIO Comparison
RDHL vs XBIO Comparison
Compare RDHL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- XBIO
- Stock Information
- Founded
- RDHL 2009
- XBIO N/A
- Country
- RDHL Israel
- XBIO United States
- Employees
- RDHL N/A
- XBIO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- XBIO Health Care
- Exchange
- RDHL Nasdaq
- XBIO Nasdaq
- Market Cap
- RDHL N/A
- XBIO 5.8M
- IPO Year
- RDHL N/A
- XBIO N/A
- Fundamental
- Price
- RDHL $1.95
- XBIO $2.47
- Analyst Decision
- RDHL
- XBIO Hold
- Analyst Count
- RDHL 0
- XBIO 1
- Target Price
- RDHL N/A
- XBIO N/A
- AVG Volume (30 Days)
- RDHL 124.9K
- XBIO 7.2K
- Earning Date
- RDHL 04-11-2025
- XBIO 05-08-2025
- Dividend Yield
- RDHL N/A
- XBIO N/A
- EPS Growth
- RDHL N/A
- XBIO N/A
- EPS
- RDHL N/A
- XBIO N/A
- Revenue
- RDHL $3,707,000.00
- XBIO $2,500,284.00
- Revenue This Year
- RDHL $224.90
- XBIO $14.23
- Revenue Next Year
- RDHL $82.69
- XBIO N/A
- P/E Ratio
- RDHL N/A
- XBIO N/A
- Revenue Growth
- RDHL N/A
- XBIO N/A
- 52 Week Low
- RDHL $1.87
- XBIO $2.26
- 52 Week High
- RDHL $20.28
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- RDHL 20.23
- XBIO 24.36
- Support Level
- RDHL $2.64
- XBIO $2.26
- Resistance Level
- RDHL $2.90
- XBIO $3.43
- Average True Range (ATR)
- RDHL 0.22
- XBIO 0.22
- MACD
- RDHL 0.02
- XBIO -0.08
- Stochastic Oscillator
- RDHL 6.99
- XBIO 12.81
Stock Price Comparison Chart: RDHL vs XBIO
■ RDHL
■ XBIO
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
Share on Social Networks:
0